---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-015629"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:52:06.377330+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech FY2023 net loss $8.4M ($2.93/sh); secures C$23M govt funding for Phase 3 ARDS trial

## Summary
- Net loss narrowed to $8.4M ($2.93 per share) from $17.6M ($8.37) in FY2022; R&D expenses fell to $4.8M from $13.3M.
- Canadian government committed up to C$23M (partially repayable) for Phase 3 study of ARDS drug EB05 (paridiprubart); FDA Fast Track granted.
- Established $10M revolving credit facility; cash and equivalents $5.4M at Sept 30, 2023, with $0.3M raised post-year-end via equity distribution.
- Plans to initiate Phase 2 trial for vitiligo drug EB06 (anti-CXCL10) and file IND for fibrotic diseases; evaluating partnership for dermatitis drug EB01 after positive Phase 2b.
- Management to present at Dermatology Summit and JP Morgan week in January 2024.

## SEC filing metadata
- accession: 0001654954-23-015629
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/0001654954-23-015629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-015629
- JSON: https://secwatch.observer/filing/0001654954-23-015629.json
- Plain text: https://secwatch.observer/filing/0001654954-23-015629.txt

## Key facts
- Earnings Releases
  Edesa Biotech, Inc. reported fiscal year ended September 30, 2023 results: net income net loss of $8.4 million, EPS $2.93 per common share.
  - Period: fiscal year ended September 30, 2023
  - Net income: net loss of $8.4 million
  - EPS: $2.93 per common share
  - Result: reported results
  source text: For the year ended September 30, 2023, Edesa reported a net loss of $8.4 million, or $2.93 per common share, compared to a net loss of $17.6 million, or $8.37 per common share, for the year ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/0001654954-23-015629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.